Shedding of membrane-bound CD14 from lipopolysaccharide-stimulated macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide

Journal of Neuroimmunology

Volumn 99, Issue 1, 1999, Pages 61-71

  Delgado, Mario ^a,b   Leceta, Javier ^a   Abad, Catalina ^a   Martinez, Carmen ^a   Ganea, Doina ^b   Gomariz, Rosa P ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

CD14; Inflammation; Lipopolysaccharide; Neuroimmunomodulation; Neuropeptides

Indexed keywords

CD14 ANTIGEN; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; NITRIC OXIDE; PHORBOL 13 ACETATE 12 MYRISTATE; TUMOR NECROSIS FACTOR ALPHA; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL CELL; ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; IMMUNOMODULATION; INFLAMMATION; MACROPHAGE ACTIVATION; MEMBRANE BINDING; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD14; FEMALE; GENE EXPRESSION REGULATION; INSECT PROTEINS; LIPOPOLYSACCHARIDES; MACROPHAGE ACTIVATION; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED BALB C; NEUROPEPTIDES; NITRIC OXIDE; PEPTIDE FRAGMENTS; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; PROTEIN KINASE C; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE, TYPE II; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; TETRADECANOYLPHORBOL ACETATE; TUMOR NECROSIS FACTOR-ALPHA; VASOACTIVE INTESTINAL PEPTIDE;

EID: 0032832033     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(99)00105-8     Document Type: Article

References (47)

1. Bazil V., Strominger J.L. Shedding as a mechanism of down-modulation of CD14 on stimulated human monocytes. J. Immunol. 147:1991;1567-1574.
2. Bozza M., Soares M.B., Bozza P.T., Satoskar A.R., Diacovo T.G., Brombacher F., Titus R.G., Shoemaker C.B., David J.R. The PACAP-type I receptor agonist maxadilan from sand fly saliva protects mice against lethal endotoxemia by a mechanism partially dependent on IL-10. Eur. J. Immunol. 28:1998;3120-3127.
3. Cosentino G., Soprana E., Thienes C.P., Siccardi A.G., Viale G., Vercelli D. IL-13 down-regulates CD14 expression and TNFa secretion in normal human monocytes. J. Immunol. 155:1995;3145-3151.
4. Delgado M., Pozo D., Martinez C., Garrido E., Leceta J., Calvo J.R., Gomariz R.P. Characterization of gene expression of VIP and VIP1-receptor in rat peritoneal lymphocytes and macrophages. Regul. Pept. 62:1996;161-166.
5. Delgado M., Munoz-Elias E.J., Kan Y., Gozes I., Fridkin M., Brenneman D.E., Gomariz R.P., Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit TNFα transcriptional activation by regulating NF-kB and CREB/c-Jun. J. Biol. Chem. 273:1998;31427-31436.
6. Delgado M., Munoz-Elias E.J., Gomariz R.P., Ganea D. VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNγ synthesis by T cells. J. Neuroimmunol. 96:1999;167-181.
7. Delgado M., Pozo D., Martinez C., Leceta J., Calvo J.R., Ganea D., Gomariz R.P. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit endotoxin-induced TNFα production by macrophages: in vitro and in vivo studies. J. Immunol. 162:1999;2358-2367.
8. Delgado M., Munoz-Elias E.J., Gomariz R.P., Ganea D. VIP and PACAP prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kB and interferon regulatory factor 1 activation. J. Immunol. 162:1999;4685-4696.
9. Delgado M., Martinez C., Pozo D., Calvo J.R., Leceta J., Ganea D., Gomariz R.P. VIP and PACAP protect mice from lethal endotoxemia through the inhibition of TNFα and IL-6. J. Immunol. 162:1999;1200-1205.
10. Delgado M., Munoz-Elias E.J., Gomariz R.P., Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. J. Immunol. 162:1999;1707-1716.
11. Dentener M.A., Bazil V., Von Asmuth E.J.U., Ceska M., Buurman W.A. Involvement of CD14 in lipopolysaccharide-induced tumor necrosis factor-a, IL-6, IL-8 release by human monocytes and alveolar macrophages. J. Immunol. 150:1993;2885-2892.
12. de Waal Malefyt R., Figdor C.G., Huijbens R., Mohan-Peterson S., Bennett B., Culpepper J., Dang W., Zurawski, de Vries J.E. Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. J. Immunol. 151:1993;6370-6378.
13. Fenton M.J., Golenbock D.T. LPS-binding proteins and receptors. J. Leukocyte Biol. 64:1998;25-32.
14. Ferrero E., Hsieh C., Francke U., Goyert S.M. CD14 is a member of the family of leucine-rich proteins and is encoded by a gene syntenic with multiple receptor genes. J. Immunol. 145:1990;331-336.
15. Ferrero E., Jiao D., Tsuberi B.Z., Tesio L., Rong G.W., Haziot A., Goyert S.M. Transgenic mice expressing human CD14 are hypersensitive to lipopolysaccharide. Proc. Natl. Acad. Sci. USA. 90:1993;2380-2384.
16. Gallay P., Jongeneel C.V., Barras C., Burnier M., Baumgartner J.-D., Glauser M.P., Heumann D. Short time exposure to lipopolysaccharide is sufficient to activate human monocytes. J. Immunol. 150:1993;5086-5092.
17. Gegner J.A., Ulevitch R.J., Tobias P.S. Lipopolysaccharide (LPS) signal transduction and clearance: dual roles for LPS binding protein and membrane CD14. J. Biol. Chem. 270:1995;5320-5325.
18. Gourlet P., Vandermeers-Piret M.C., Ratche J., De Neef P., Robberecht P. Fragments of the pituitary adenylate cyclase activating polypeptide discriminate between types I and II recombinant receptors. Eur. J. Pharmacol. 287:1995;7-11.
19. Gourlet P., Vandermeers A., Vertongen P., Ratche J., De Neef P., Cnudde J., Waelbroeck M., Robberecht P. Development of high affinity selective VIP1 receptor agonists. Peptides. 18:1997;1539-1545.
20. Gourlet P., De Neef P., Cnudde J., Waelbroeck M., Robberecht P. In vitro properties of a high affinity selective antagonist of the VIP1 receptor. Peptides. 18:1997;1555-1560.
21. 131I -labeled human growth hormone of high specific radioactivity Biochem. J. 89:1963;114-118.
22. Harmar A.J., Arimura A., Gozes I., Journot L., Laburthe M., Pisegna J.R., Rawlings S.R., Robberecht P., Said S.I., Sreedharan S.P., Wank S.A., Washeck J.A. Nomenclature of receptors for vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP). Pharmacol. Rev. 50:1998;625-627.
23. Haziot A., Chen S., Ferrero E., Low M.G., Silber R., Goyert S.M. The monocyte differentiation antigen, CD14, is anchored to the cell membrane by a phosphatidylinositol linkage. J. Immunol. 141:1988;547-554.
24. Haziot A., Ferrero E., Kontgen F., Hijiya N., Yamamoto S., Silver J., Stewart C.L., Goyert S.M. Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD14-deficient mice. Immunity. 4:1996;407-414.
25. Heumann D., Gallay P., Barras C., Zaech P., Ulevitch R.J., Tobias P.S., Glauser M., Baumgartner J.D. Control of lipopolysaccharide (LPS) binding and LPS-induced tumor necrosis factor secretion in human peripheral blood monocytes. J. Immunol. 148:1992;3505-3512.
26. Kitchens R.L., Wang P.-Y., Munford R.S. Bacterial lipopolysaccharide can enter monocytes via two CD14-dependent pathways. J. Immunol. 161:1998;5534-5545.
27. Kriegsmann J., Gay S., Brauer R. Endocytosis of lipopolysaccharide in mouse macrophages. Cell. Mol. Biol. 39:1993;791-798.
28. Lauener R.P.L., Goyert S.M., Geha R.S., Vercelli D. Interleukin-4 down-regulates the expression of CD14 in normal human monocytes. Eur. J. Immunol. 20:1990;2375-2381.
29. Martinez C., Delgado M., Pozo D., Leceta J., Calvo J.R., Ganea D., Gomariz R.P. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide modulate endotoxin-induced IL-6 production by murine macrophages. J. Leukocyte Biol. 63:1998;591-601.
30. Martinez C., Delgado M., Abad C., Gomariz R.P., Ganea D., Leceta J. Regulation of VIP production and secretion by murine lymphocytes. J. Neuroimmunol. 93:1999;126-138.
31. Medzhitov R., Janeway C.A. Innate immunity: the virtues of a nonclonal system of recognition. Cell. 91:1997;295-298.
32. Medzhitov R., Preston-Hurlbut P., Janeway C.A. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 388:1997;394-397.
33. Moro O., Lerner E.A. Maxadilan, the vasodilator peptide from sand flies, is a specific pituitary adenylate cyclase activating polypeptide type I receptor agonist. J. Biol. Chem. 271:1996;966-970.
34. Morrison M. Lactoperoxidase-catalyzed iodination as a tool for investigation of proteins. Meth. Enzymol. 70:1980;214-218.
35. Pedron T., Girard R., Chaby R. Variation of LPS-binding capacity, epitope expression, and shedding of membrane-bound CD14 during differentiation of human monocytes. J. Immunol. 155:1995;1460-1471.
36. Pozo D., Delgado M., Martinez C., Gomariz R.P., Guerrero J.M., Calvo J.R. Functional characterization and mRNA expression of pituitary adenylate cyclase activating polypeptide (PACAP) type I receptor in rat peritoneal macrophages. Biochim. Biophys. Acta. 1259:1997;250-262.
37. Qureshi S.T., Lariviere L., Leveque G., Clermont S., Moore K.J., Gros P., Malo D. Endotoxin-tolerant mice have mutations in toll-like receptor 4 (Tlr-4). J. Exp. Med. 189:1999;615-625.
38. Rawlings S.R., Hezareh M. Pituitary adenylate cyclase activating polypeptide and PACAP/vasoactive intestinal polypeptide receptors: actions in the anterior pituitary gland. Endocr. Rev. 17:1996;4-29.
39. Schimke J., Mathison J., Morgiewicz J., Ulevitch R.J. Anti-CD14 mAb treatment provides therapeutic benefit after in vivo exposure to endotoxin. Proc. Natl. Acad. Sci. USA. 95:1998;13875-13880.
40. Schumann R.R., Leong S.R., Flaggs G.W., Gray P.W., Wright S.D., Mathison J.C., Tobias P.S., Ulevich R.J. Structure and function of lipopolysaccharide binding protein. Science. 249:1990;1429-1431.
41. Simmons D.L., Tan S., Tenen D.G., Nicholson-Weller A., Seed B. Monocyte antigen CD14 is a phospholipid-anchored membrane protein. Blood. 73:1989;284-291.
42. Soares M.B., Titus R.G., Shoemaker C.B., Davi J.R., Bozza M. The vasoactive peptide maxadilan from sand fly saliva inhibits TNF-a and induces IL-6 by mouse macrophages through interaction with the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor. J. Immunol. 160:1998;1811-1816.
43. Takeshita S., Gage J.R., Kishimoto T., Vredovoe D.L., Martinez-Maza O. Differential regulation of IL-6 gene transcription and expression by IL-4 and IL-10 in human monocytic cell lines. J. Immunol. 156:1996;2591-2598.
44. Tamura G.S., Dailey M.O., Gallatin W.M., McGrath M.S., Weissman I.L., Pillemer E.A. Isolation of molecules recognized by monoclonal antibodies and antisera: the solid-phase immunoisolation technique. Anal. Biochem. 136:1984;458-463.
45. Wright S.D., Ramos R.A., Tobias P.S., Ulevitch R.S., Mathison J.C. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science. 249:1990;1431-1433.
46. Xin Z., Sriram S. Vasoactive intestinal peptide inhibits IL-12 and nitric oxide production in murine macrophages. J. Neuroimmunol. 89:1998;206-212.
47. Yang R.-B., Mark M.R., Gray A., Huang A., Xie M.H., Zhang M., Goddard A., Wood W.I., Gurney A.L., Godowski P.J. Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signaling. Nature. 395:1998;284-288.